Sanofi (SNY) Liabilities and Shareholders Equity (2009 - 2026)

Sanofi has disclosed Liabilities and Shareholders Equity across 18 years of filings, most recently posting $150.0 billion for Q2 2026.

• In Q2 2026, Liabilities and Shareholders Equity rose 6.06% year-over-year to $150.0 billion; the TTM figure through Jun 2026 stood at $599.2 billion (up 41.97% YoY), while the FY2025 annual figure was $147.6 billion, up 2.7% from the prior year.
• Liabilities and Shareholders Equity came in at $150.0 billion for Q2 2026 at Sanofi, roughly flat from $149.9 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $151.7 billion in Q3 2025 to a low of $129.3 billion in Q4 2022.
• Average Liabilities and Shareholders Equity over 5 years is $141.1 billion, with a median of $140.6 billion recorded in 2025.
• Year-over-year, Liabilities and Shareholders Equity retreated 6.01% in 2022 and grew 8.04% in 2026.
• Over 5 years, Liabilities and Shareholders Equity stood at $129.3 billion in 2022, then climbed by 5.24% to $136.1 billion in 2023, then climbed by 4.29% to $141.9 billion in 2024, then grew by 4.02% to $147.6 billion in 2025, then climbed by 1.63% to $150.0 billion in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $150.0 billion in Q2 2026, $149.9 billion in Q1 2026, and $147.6 billion in Q4 2025.